You are here

A Unique Deployable Thermosensor Probe for the Minimally Invasive Treatment of Renal Tumors

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA224431-01A1
Agency Tracking Number: R43CA224431
Amount: $300,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 102
Solicitation Number: PA17-302
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-07-17
Award End Date (Contract End Date): 2020-06-30
Small Business Information
Owego, NY 13827-1515
United States
DUNS: 150225337
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (607) 427-3459
Business Contact
Phone: (607) 687-8701
Research Institution

The use of thermal therapies such as radio frequency ablationRFAor cryoablation to ablate
tissue for the treatment of numerous diseases ranging from renal cancer to cardiac arrhythmias
continues to grow in popularity and efficacyWhile several treatment options currently exist for
renal cancerRCCanalysis of survival trends reveals that RCC has therd lowest
improvement in overall survival sinceandltdecrease in the lastyearstrailing only
pancreaticand bladdercancersWhile partial nephrectomy is currently one of the
most common optionsan increasing number of older patients are now electing either heatRFAor freezingcryoablationas a preferred optiongiven their documented similar
oncologic outcomes compared to partial nephrectomydue to the less invasive nature of the
thermal percutaneous treatment andwhen patients are of advanced ageexhibit severe
comorbidities such cardiovascular and pulmonary diseasesor have hereditary RCCBiopsy
analysis is critical to defining and tracking the success of the treatment modalityThis Phase I
application is formulated based on the advances in thermal ablation and its increasing
applications in treating RCCCPSI Biotech is a medical device company that specializes in
thermal ablation technology and has developed the Super Critical NitrogenSCNand
Pressurized Sub cooled NitrogenPSNmedical devices now in pre clinical trialsGiven the
increase in the use of thermal ablative technologies to treat a variety of diseases such as RCC
coupled to the fact that CPSI has shown that using freezing and heat together in a dual thermal
ablationDTAparadigm can be more effective than either heat or freezing alonewe propose to
develop a unique percutaneous thermal probeQuadProbeRCCthat canafreezebheatcdeploy a thermosensor that is incorporated into the cryoprobe anddretrieve a biopsy of the
targeted tissueThis multi functional probe will also be capable of performing DTA treatment of
RCCSpecific Aims are the followingSADevelop QuadProbe RCC and test in non tissue
systemsSATest the QuadProbe RCC in tissue engineered and in vivo modelsIf this
project meets the Phase I feasibility criteriaPhase II will propose to further develop this probe
technology platform enabling the administration of combinatorial drug ablation treatment
paradigms including using thermal sensitizer designed to make freezingheat or DTA more
effectiveThis platform will also enable the monitoring of target tissue temperature in real time
without the need of multiple external thermal sensors which is the current state of the art for
thermal ablation treatment paradigms This application proposes to develop a novel deployable multipoint temperature sensing
dual thermal ablation probe and biopsy technology for the treatment of renal and other
urologic cancers

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government